Although the clinical implication of frailty is undoubtably important, many patients are underdiagnosed and the need for effective screening tools are warranted (10).Alanine transaminase (ALT) is an enzyme generally utilized to assess liver damage, however ALT levels are a marker for skeletal muscle mass and low levels are associated with sarcopenia and frailty (11, 12). This evidence concerns the gene GPT and sarcopenia.